Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
In the first year following diagnosis, we found increased cumulative incidence risk ratios in a number of outcomes including: - Any mental, behavioural, or neurodevelopmental disorder 1.96 (1.93 - 1.99) - Postpartum depression 2.70 (2.61 - 2.79) - Eating disorders 2.06 (1.85 - 2.89) - PTSD 1.77 (1.69 - 1.86) We also saw significantly increased risk in rare but serious outcomes such as: - Wernicke's encephalopathy 2.39 (1.25 - 4.56) - Puerperal psychosis 1.80 (1.48 - 2.20) Interestingly, cases of hyperemesis gravidarum with metabolic disturbance displayed a significantly lower risk of any depression and postpartum depression compared with those without metabolic disturbance
Temperature control during shipping is critical but variable
As for medical use, BPC-157 may only be used for research purposes with special permission (as in the two pilot studies mentioned above) and may not be sold to the public or even prescribed by medical doctors, according to the U.S
Recommend patch testing for end-users to ensure compatibility (Pickart, 2010)
